Clinical trial
UX023-EAP
Name
UX023-EAP
Description
Individual patient expanded access requests may be considered for patients who have no other treatment options
Trial arms
Treatment
Burosumab
Other names:
UX023, Crysvita®, KRN23
Size
-1
Eligibility criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Protocol
{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 7, 'expandedAccessTypes': {'individual': True}}
Updated at
2024-03-05
1 organization
1 product
2 indications
Organization
Ultragenyx PharmaceuticalProduct
BurosumabIndication
X-linked hypophosphatemiaIndication
Tumor-Induced Osteomalacia